A phase III trial comparing the PD-1 inhibitor nivolumab to VEGF-A inhibitor bevacizumab showed no improvement in survival in patients with recurrent GBM (CheckMate-143) [8•]. The gene discussed is PDCD1; the disease is glioblastoma.